The present invention relates to substituted xanthines of general formula 1wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV. The method comprises a first step for determining \u201cextra-wide lane\u201d carrier phase ambiguity, a second step for estimating \u201cwide-lane\u201d phase ambiguity, and a third step for resolving the phase ambiguity of one of the frequencies. Both static and dynamic content insert positions are supported. The device is used in a stand alone audio circuit and does not require connection into a band’s complete audio system. In this laser device, when the light input to the monitor unit has an intensity equal to or higher than a predetermined intensity while the seed light is not input to the amplification optical fiber, the light source controller forces to output the seed light from the seed light source. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.